1 documents found
Information × Registration Number 0107U012640, R & D request Title Clinical investigation Phase III: Multicentered, double, blind, placebo-controlled, 24-week investigation in parallel groups for efficacy and safety evaluation of Tsertolizumab Pegol (fluid) in 2 doses as auxiliary treatment in combination with Metotrexat for elimination of signs and symptoms of rheumatoid arthritis as well as for prophylaxis of joint injury in patients with active rheumatoid arthritis in partial respond to Metotrexat Head Лисенко Григорій Іванович, Registration Date 27-12-2007 Organization Shupyk National Medical Academy of Postgraduate Education popup.description1 popup.nrat_date 2024-12-10 Close
search.res_rk
Clinical investigation Phase III: Multicentered, double, blind, placebo-controlled, 24-week investigation in parallel groups for efficacy and safety evaluation of Tsertolizumab Pegol (fluid) in 2 doses as auxiliary treatment in combination with Metotrexat for elimination of signs and symptoms of rheumatoid arthritis as well as for prophylaxis of joint injury in patients with active rheumatoid arthritis in partial respond to Metotrexat
Head: Лисенко Григорій Іванович. Clinical investigation Phase III: Multicentered, double, blind, placebo-controlled, 24-week investigation in parallel groups for efficacy and safety evaluation of Tsertolizumab Pegol (fluid) in 2 doses as auxiliary treatment in combination with Metotrexat for elimination of signs and symptoms of rheumatoid arthritis as well as for prophylaxis of joint injury in patients with active rheumatoid arthritis in partial respond to Metotrexat. Shupyk National Medical Academy of Postgraduate Education. № 0107U012640
1 documents found

Updated: 2026-03-22


Роздрукувати цю сторінку